By Raveena Bhambra
Q2 was full of deals, coupled with the talk of potential deals, and overall it finished on a high with a large volume of agreements coming together in June.
- Over 500 partnership deals announced during Q2
- Four deals valued at over $1billion
- The leading therapy deal of the quarter was a partnership focused on Crohn’s disease
- Pfizer was the most active big pharma dealmaker
The following article is a summary of the key partnership deal pharma trends of Q2 covering highest value deals, top industry and therapy deals. We also look at the top five deals by headline value during the period and display their details, plus links to each full deal record are supplied by our proprietary deals and alliances database Current Agreements.
The remaining part of this article is Premium content – see below for access options.
Purchase this article
$35.00 BUY NOW
For $35.00, purchase this 3,095-word article and receive immediate online access.
100% Satisfaction Guarantee.
Report: Bigpharma Deals and Alliances of 2013
Report: Merger and Acquisition Deals and Alliances of 2013
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity
Current Partnering provides industry executives with partnering best practice and essential business intelligence. Further details about the range of reports and subscription services offered can be found at our website:
This article was published July 2014.
For inquiries about the content of this article, please contact:
Mail: Current Partnering
Wildwood Ventures Ltd
All rights reserved.